Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

NCT03805841 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped enrollment pause

Conditions

NSCLC, Stage IV
NSCLC Stage IIIB
NSCLC, Stage IIIC
NSCLC, Recurrent
EGFR Exon 20 Insertion Mutation
HER2-activating Mutation
ERBB Fusion
NRG1 Fusion

Interventions

DRUG: tarloxotinib bromide

Sponsor

Rain Oncology Inc